Mucosal damage to the intestines induced by myeloablative conditioning for allogeneic PBSC transplant (PBSCT) can be determined by the concentration of citrulline, which is a functional marker of small intestinal enterocytes. Low citrulline concentrations in blood coincide with and are a response to severe mucosal barrier injury. We treated 29 patients with high-dose melphalan 200 mg/m 2 (Mel-200) to prepare for an autologous PBSCT and collected plasma samples from each patient starting before the myeloablative regimen and three times per week thereafter until discharge. The baseline citrulline concentration was 27.6 mM±4.0 (mean±95% confidence interval; CI), and citrulline concentrations declined rapidly thereafter reaching a nadir averaging 6.7 mM ± 2.7, 12 days after starting Mel-200. Citrulline concentrations, only increased gradually and were still low (12 mM ± 4) at discharge. A total of 20 patients developed fever, which was associated with bacteraemia in 10 cases. Their mean citrulline concentrations were lower at 5.5 mM ± 1.5 than were those of patients without bacteraemia (10.2 mM ± 3.9). Importantly, neither the number of preceding neutropenic days nor the mean C-reactive protein (CRP) concentration at the onset of fever was different between these two groups. In conclusion, citrulline concentrations rapidly decline after Mel-200 reflecting intestinal mucosal barrier injury. Low citrulline, rather than the duration of neutropenia, is associated with bacteraemia indicating the importance of an intact mucosal barrier in neutropenic patients.
Introduction
Mucositis is the clinical manifestation of mucosal barrier injury and is the most frequent cause of morbidity associated with myeloablative treatment to prepare for haematopoietic SCT (HSCT). 1 Impaired integrity of the mucosal barrier induced by anticancer therapy is thought to promote translocation of microorganisms from the lumen of the digestive tract to the blood stream resulting in bacteraemia. 2 Whereas oral mucositis is relatively easy to recognize, detection of intestinal mucosal injury is more demanding. Recently, it was shown that citrulline appeared to be particularly useful to detect gut damage, as blood concentrations of this amino acid directly reflect functioning small intestinal cell mass. 3 Furthermore, low plasma concentrations of citrulline coincided with the mucosal barrier injury of the small intestine induced by the intensive myeloablative therapy used to prepare for a T-cell depleted allo-SCT. These levels also corresponded to the severity and extent of gut injury. 4 We explored the kinetics of citrulline concentrations in a cohort of patients treated with 200 mg/m 2 melphalan (Mel-200) to prepare for an autologous PBSC transplant (PBSCT). Furthermore, we determined the relationship of citrulline concentrations to bacteraemia, as the risk is known to be increased by mucositis. 5 
Patients and methods

Patient management
From May 2004 to May 2005, 29 consecutive patients (12 female; 17 male) with a mean age of 55 years (range: 30-65 years) were admitted to undergo an autologous PBSCT to treat multiple myeloma. Each patient was managed with a triplelumen central venous catheter and received melphalan at a dose of 100 mg/m 2 on days -3 and -2 before transplant. Each patient received parenteral nutrition from the day of transplant onwards and ondansetrone as an antiemetic. Anti-infective prophylaxis consisted of ciprofloxacin and valaciclovir. Fluconazole was given only to patients who were colonized by Candida albicans. No haematopoietic growth factors or keratinocyte growth factors were used.
Defining bacteraemia
At the onset of fever (single axillary temperature of X38.5 1C) during neutropenia (neutrophil count of o0.5 Â 10 9 /l), a single 10 ml sample of blood was obtained from each lumen of the central venous catheter and inoculated into an aerobic BACTEC plus (BD Diagnostic Systems, Sparks, USA) blood culture bottle. A further two 20 ml samples of blood were drawn from separate peripheral veins and were each inoculated equally into a blood culture set comprising an aerobic and anaerobic BACTEC plus culture bottle. Ceftazidime was administered immediately afterwards. Bacteraemia was defined by any single blood culture-yielding bacteria except for coagulase-negative staphylococci, which required the same strain to be recovered from two separate cultures. C-reactive protein (CRP) was measured daily until discharge using turbidimetric immunoassay (Aeroset, Abbott Laboratories, Illinois, USA).
Citrulline analysis
Blood was collected in heparin from each patient through the central venous catheter before starting therapy and on each Monday, Wednesday and Friday thereafter until discharge. Plasma was prepared and stored at -80 1C for later analysis. Citrulline concentrations (mM) were measured by a standard procedure for determining amino acids using high-performance liquid chromatography (Shimadzu, Kyoto, Japan). 6 Oral mucositis assessment Oral mucositis was scored daily by trained nurses who recorded the presence of pain, lesions, erythema, oedema, bleeding, dryness and of viscous mucus allocating a score of 0 for normal to 3 for severe. 7 The separate values were summed up to yield a daily oral mucositis score.
Gut mucositis assessment
Gut toxicity was determined from the frequency of vomiting and diarrhoea, the occurrence of nausea, abdominal complaints, faecal incontinency and the volume of diarrhoea. Each item was scored from 0 (normal) to 3 (severe) and the values were summed to yield the daily gut score. 1 All gut toxicities developed following chemotherapy were attributed to mucositis unless there was a more plausible alternative cause such as an adverse drug reaction or a proven infection.
Data analysis SPSS for windows software (release 12.1). was used for statistical analysis. All results are expressed as the mean and 95% CI. The time course of citrulline was estimated from the day cytotoxic therapy was given (day 1). 8 The number of days with neutropenia before the onset of fever was counted and the daily oral mucositis score, daily gut score, the concentrations of citrulline and CRP, and the absolute leukocyte and neutrophil count on that day were noted. Missing data were replaced with the values for the day before or after the onset of fever. A two-sided unpaired Student's t-test was used to calculate significant differences with respect to baseline. Analysis of variance was used to test differences between and within groups. A P-value of o0.05 was considered statistically significant. After start of chemotherapy, citrulline concentrations decline rapidly, reaching a nadir on day 12 after starting cytostatic chemotherapy (HSCT day þ 8).
Citrulline concentrations only increased gradually but remain low at discharge from hospital. HSCT, haematopoietic SCT.
Results
All patients had an estimated renal creatinine clearance above 50 ml/l at admission using the Cockcroft and Gault formula, 9 and no adjustments were made to the dose of melphalan. None of the patients developed an invasive fungal disease and all survived the first 6 weeks after transplant.
The average citrulline concentration (mean ± 95% CI) at baseline for all patients was 27.6 mM±4.0, and concentrations declined rapidly thereafter reaching a nadir averaging 6.7 mM ± 2.7 on day þ 8 of PBSCT (12 days after starting Mel-200) (Figure 1 ). Citrulline concentrations then increased gradually but were still markedly low with a mean of 12 mM ± 4 at discharge.
All patients became profoundly neutropenic (mean onset HSCT day þ 4.5±0.3) with a mean duration of neutropenia of 10.2 days ± 2.7. 20 patients (69%) developed fever that was accompanied by bacteraemia in 10 cases, five of which were due to a single species (two Streptococcus mitis, two Staphylococcus epidermidis and one Staphylococcus haemolyticus) and five due to two species (one case each of S. mitis and S. epidermidis, S. mitis and Staphylococcus hominis, S. mitis and Staphylococcus capitis, S. epidermidis and S. hominis and S. epidermidis and Staphylococcus saprophyticus). Cultures drawn from peripheral and from central lines yielded the same bacteria. The mean citrulline level at the onset of fever among patients with bacteraemia was 5.5 mM ± 1.5 and was significantly lower than that of patients without bacteraemia (10.2 mM±3.9; Po0.05). However, there was no difference in the time to the onset of fever from neutropenia, in CRP concentrations, leukocyte counts daily gut score or daily oral mucositis score on the day of fever between the groups (Table 1) . Neither was a difference found between the mean baseline citrulline concentrations, which were, respectively, 23.0 mM ± 3.5 for patients with bacteraemia compared with 31.3 mM±3.4 for those without bacteraemia.
Discussion
The plasma concentrations of all patients' citrulline reached a nadir within 12 days after starting myeloablative therapy indicating intestinal mucosal damage, with the lowest citrulline concentrations coinciding with the onset of bacteraemia. Patients with bacteraemia had significantly lower citrulline concentrations on the first day of fever than did those without bacteraemia. But there was no difference in the total days before the onset of fever after patients became neutropenic. This suggests that the severity of gut mucosal barrier injury determines whether bacteraemia occurs or not rather than neutropenia per se.
Neutropenia (granulocytes o0.5 Â 10 9 /l) has been used for 40 years to recognize those patients who are at imminent risk of developing infectious complications following intensive chemotherapy. 10 This formed the foundation for developing a successful strategy for managing these patients, namely administering broad-spectrum antimicrobial therapy promptly as soon as fever occurs during neutropenia. Indeed, empirical antibacterial therapy is still the backbone of the supportive care given to these patients. 11 However, it has become clear that mucosal barrier injury plays a distinct role in determining the outcome of SCT. 12 With mucosal damage being indicated by declining citrulline levels, we may be able to identify more effectively the risk period for developing bacteraemia in neutropenic patients. Of the 29 patients we investigated, 20 became febrile but only half of them developed bacteraemia, and their citrulline concentrations were lower than those found in the other patients. Morever, these concentrations correspond to diffuse total villous atrophy. 3 Interestingly, the maximum World Health Organization scale grade of oral mucositis was also shown to occur on day 12 after starting cytostatic chemotherapy. 13 In our study, neither daily oral mucositis score nor daily gut score was significantly different between those with and without bacteraemia, confirming that these instruments measure different features of digestive tract injury compared to citrulline concentrations. 14 We also found that CRP was not useful for detecting or predicting bacteraemia as has been noted by others. 15, 16 Most likely, this is because CRP marks a response to a variety of stimuli other than infection and its elaboration is relatively slow. However, the time course of CRP is relevant. A study with rats treated with 5-fluorouracil (5-FU) showed that the release of proinflammatory cytokines was associated with evolving gut mucosal damage and preceded bacterial translocation. 17 Consequently, an increase in CRP levels may reflect the severity of gut mucosal damage. 4 All the episodes of bacteraemia that we observed were due either to coagulase-negative staphylococci or viridans Table 1 Mean ± 95% CI of citrulline concentrations, DMS, DGS, CRP and leukocytes on the first day of fever and total neutropenic days before the onset of fever in patients with neutropenic fever with or without bacteraemia streptococci. This is most likely a direct consequence of giving ciprofloxacin as prophylaxis, which effectively prevents bacteraemia due to Gram-negative bacilli, while giving selective advantage to the less susceptible Grampositive bacteria. 18 The blood cultures of 5 of the 10 patients with bacteraemia yielded two bacterial species that might simply reflect greater sampling efficiency, as we obtained a total of 70 ml of blood for blood cultures, which is more than others report 19 Viridans streptococci are primarily oral commensal flora; however, molecular analysis of the microbiota in the stomach shows that these bacteria can be found in large numbers along with Helicobacter pylori. 20 In children treated for AML, there was an association between the presence of gastrointestinal toxicity and the development of viridans group streptococcal bacteraemia. 21 Similarly, coagulase-negative staphylococci have been assumed to originate from central venous catheters. However, there is a growing body of evidence that these bacteria may, in fact, also originate from the gastrointestinal tract. 22 Indeed, molecular analysis of coagulase-negative staphylococci isolated from blood cultures indicated that the mucosa was the origin in most of the cases. 23 Moreover, bacteraemia due to these staphylococci has been shown to occur mostly within the first 2 weeks after transplant when gut integrity is markedly disturbed.
A recent study reported a threefold increase in documented infections in patients with gastrointestinal mucositis, though there was no relationship between mucositis and the depth or duration of neutropenia. 24 Our results concur suggesting that mucosal barrier injury is an independent risk factor for the bacterial translocation that precedes bacteraemia. A small study of Ellis et al. 25 showed that treatment with recombinant human IL-11 resulted in less bacteraemia and that, although a protective effect on the mucosa was not observed, gut permeability improved. Hence, agents such as recombinant human IL-11 and the keratinocyte growth factor palifermin, 26 which are designed to protect the mucosa, may prove helpful in reducing bacterial infection in neutropenic patients. Indeed, in the recent study of palifermin, there were fewer episodes of bacteraemia among those given the drug than was found among those given placebo (15 vs 25%). However, the difference was not statistically significant and no details were provided on the aetiology of bacteraemia.
Severe disruption of the mucosal barrier is clearly not the only risk factor for developing bacteraemia, which affected only a third of our patients with low citrulline concentrations. To identify those patients at risk for bacteraemia, citrulline measurements need to be combined with other tests. For instance, the Multinational Association of Supportive Care of Cancer (MASCC) developed a risk score to predict at the onset of fever during neutropenia which patients are at high risk for development of serious medical complications. 27 Endothelial cells, such as the epithelial cells of the gut, play an important part in the innate immune system in neutropenic patients and produce IL-8 when exposed to bacteria. 28 Hence, perhaps monitoring IL-8 levels 29, 30 combined with the MASCC risk score, when patients have low citrulline concentrations, might help distinguish those at risk of developing bacteraemia from those who are not.
In conclusion, this study provides more evidence that the damage induced by cytostatic chemotherapy to the mucosa plays an important role in the morbidity and mortality after intensive chemotherapy. Preventing or restoring damage to the mucosa may offer a more effective means of preventing bacteraemia after transplant than giving antimicrobial agents. Citrulline may provide added utility in the diagnostic work-up of neutropenic patients to help recognize those who are at increased risk for developing bacteraemia.
